Educational Video for Childhood Cancer

Recruiting in Palo Alto (17 mi)

Overseen BySuzanne MacFarland, MD

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Children's Hospital of Philadelphia

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial aims to develop and test an informational video about genetic testing for children and adolescents newly diagnosed with cancer or tumors. The video explains why both cancer tissue and normal tissue are tested, helping families understand the process and its benefits. By providing this information, the trial seeks to support families and improve their experience during a challenging time.

Eligibility Criteria

This trial is for children and adolescents aged 12 or older with a new diagnosis of cancer, tumors, or genetic disorders. Participants must be able to understand and speak English fluently without cognitive impairments that limit comprehension. It's also open to parents/legal guardians of these patients at the Children's Hospital of Philadelphia.

Inclusion Criteria

Ages 12+

Adolescent/Young Adult (AYA) probands: Child proband receiving germline testing in the Cancer Center at CHOP

Appropriate to approach per oncology team

+4 more

Exclusion Criteria

You do not meet any of the requirements to be included in the study.

Participant Groups

The study is testing an educational video designed to inform about paired tumor/normal genetic testing in young patients with cancer or other related diagnoses. The goal is to assess how acceptable, feasible, and effective this video is as a resource.

2Treatment groups

Experimental Treatment

Active Control

Group I: With VideoExperimental Treatment1 Intervention

In year 2, investigators will recruit families of patients receiving the updated standard-of-care approach to tumor-normal genetic testing with provider based education and an educational video.

Group II: Without VideoActive Control1 Intervention

In year 1, investigators will recruit families of patients receiving the current standard-of-care approach to tumor-normal genetic testing with provider based education.